Nos

0

essais cliniques ouverts

Vous êtes patient : votre médecin est à votre disposition pour vous expliquer si votre pathologie vous rend eligible à un essai.

Qu’est ce qu’un essai clinique ?

Plus d’informations via l’INCa

Vous êtes médecin : Vous avez un patient éligible à l’un de ces essais ? Nous vous invitons à joindre le contact indiqué pour chaque essai.

Date de mise à jour: Novembre 2021

TOUS
LES
ESSAIS

NCTTitre de l’essaiPhaseIndicationAltération génétique/marqueurCritères d’inclusionStadeligne de traitementContactSite d’inclusion
NCT04163887Effect of the Laparoscopic Approach in Reducing Postoperative Severe Complications Following Hepatectomy for Colorectal Liver Metastases (METALAP)Non Applicable / ChirurgieMétastase hépatique de cancer du colonCritèresMetastatiquedavid.fuks@aphp.frCochin
NCT04791735Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma (LapCHC)Non Applicable / ChirurgieCarcinome hépatocellulaireCritèresSolitary or multifocal resectabledavid.fuks@aphp.frCochin
NCT03679169Evaluation of Complete microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy (REMIND-01)Non Applicable / ChirurgieCancer du pancréasCritèresInvasive resectabledavid.fuks@aphp.frCochin
NCT03968419This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)2Cancer du poumon non à petites cellules (NSCLC)CritèresStade IB-IIIA1marie.wislez@aphp.frCochin
NCT03447769Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer (Canopy-A)3Cancer du poumon non à petites cellules (NSCLC)CritèresIIA-IIIA and IIIB (atteintes résiduelles N2 seulement)2marie.wislez@aphp.frCochin
NCT03924869Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)3Cancer du poumon non à petites cellules (NSCLC)CritèresI or IIA1marie.wislez@aphp.frCochin
NCT04026412A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)3Cancer du poumon non à petites cellules (NSCLC)CritèresLocally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) 1marie.wislez@aphp.frCochin
NCT03977194Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY)3Cancer du poumon non à petites cellules (NSCLC)Critèresmetastatic1marie.wislez@aphp.frCochin
NCT04547504PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE)3Cancer du poumon non à petites cellules (NSCLC)PDL1 (expression >50%)CritèresStage IV or . Unresectable and non-eligible to radiotherapy stage III 1marie.wislez@aphp.frCochin
NCT04475939Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L)3Cancer du poumon non à petites cellules (NSCLC)Without known alterationCritèresAdvanced (Stage IIIB not amenable to definitive chemoradiotherapy) or metastatic (Stage IV) 2marie.wislez@aphp.frCochin
NCT04194944A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)3Cancer du poumon non à petites cellules (NSCLC)Ret-fusionCritèresAdvanced or metastatic : Stage IIIB-IIIC or Stage IV1marie.wislez@aphp.fr / francoise.lepimpec-barthes@aphp.frCochin/HEGP
NCT04323436Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations2Cancer du poumon non à petites cellules (NSCLC)METΔex14 mutationCritères locally advanced or metastatic 1marie.wislez@aphp.frCochin
NCT04233021Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL)2Cancer du poumon non à petites cellules (NSCLC)EGFRCritèresmetastatic (Leptomeningeal &
Brain)
2, 3 or 4marie.wislez@aphp.frCochin
NCT03940703A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)2Cancer du poumon non à petites cellules (NSCLC)MET Amplified, EGFRCritèresLocally advanced or metastatic2marie.wislez@aphp.frCochin
NCT04111705Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)2Cancer du poumon non à petites cellules (NSCLC)ALK rearrangementCritèreslocally advanced or metastatic (Stage IIIB or IV )2marie.wislez@aphp.frCochin
NCT03351361Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (eNERGY)3Cancer du poumon non à petites cellules (NSCLC)CritèresStage IV or non-treatable by radiotherapy or surgery stage III1marie.wislez@aphp.frCochin
NCT02912949A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion1,2 : First in humantumeurs solides / NSCLC / cancer du pancréas NRG1 FusionNRG1 fusionCritères 2marie.wislez@aphp.frCochin
NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)3Cancer du poumon à petites cellules (SCLC)Critèreslocally (Limited-Stage SCLC (Stage I-III)1marie.wislez@aphp.frCochin
NCT04120701Circulating tumor dna based decision for adjuvant treatment in colon cancer stage II

3Cancer du colonCritèresAdjuvant/Stage II-AdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT02945033Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk (ASPIK French)3Cancer du colonPI3KCritèresAdjuvant/Stage II-IIIAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT02967289A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high- risk stage III colon cancer in adjuvant setting 
3Cancer du colonCritèresAdjuvant/Stage IIIAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT02355379Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more3Cancer du colonCritèresAdjuvant/Stage IIIAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT02885753Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR)3Cancer du colonCritèresMétastases hépatiques1Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.frHEGP/Cochin
NCT03164655A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy: SULTAN (improving SUrgery of Liver metastases: a Trial of the Arterial chemotherapy Network) 2Cancer du colonCritèresMétastases hépatiques2Julien Taieb : jtaieb75@gmail.comHEGP
NCT04456699A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) 
3Cancer du colonCritèresMétastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT03584711A Phase II Study Evaluating FOLFOX + Panitumumab According to a « Stop and go » Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation2Cancer du colonRAS wt; BRAF wtCritèresMétastatique1Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.frHEGP/Cochin
NCT04034459FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC2Cancer du colonBRAF muté (V600E).   RAS wtCritèresMétastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT03186326Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO)2Cancer du colonMSICritèresMétastatique2Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.frHEGP/Cochin
NCT04392479TWICE-IRI: Optimization of second-line therapy with aflibercept, irinotecan (day 1 or day 1,3), 5-Fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study. 
3Cancer du colonCritèresMétastatique2Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.frHEGP/Cochin
NCT03829462A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D1 3Cancer du colon génotype A/A (rs9344) de la cycline D1 

CritèresMétastatique≥2Julien Taieb : jtaieb75@gmail.comHEGP
NCT04737187Phase III study of trifluridine/tipiracil in combination with bevacizumab vs trifluridine/tipiracil single agent in patients with refractory metastatic colorectal cancer 3Cancer du colonCritèresMétastatique2,3Julien Taieb : jtaieb75@gmail.comHEGP
NCT04450836Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT)2Cancer du colonCritèresMétastatique≥2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03875781Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemotherapy followed by chemoradiotherapy for locally advanced resectable rectal cancer 2Cancer du RectumCritèresPré-opératoirePré-opJulien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.frHEGP/Cochin
NCT04543617A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy3Carcinome Epidermoïde de l’oesophageCritèresLA1Julien Taieb : jtaieb75@gmail.comHEGP
NCT03748134Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma3Carcinome Epidermoïde de l’oesophageCritèresLA-Métastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT03719924Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma3Carcinome Epidermoïde de l’oesophageCritèresMétastatique2Julien Taieb : jtaieb75@gmail.comHEGP
NCT04006262Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma2Adénocaecinome oeso-gastrique dMMR et/ou MSICritèresPéri-opPéri-opJulien Taieb : jtaieb75@gmail.comHEGP
NCT03006432Phase III randomised trial to evaluate FOLFOX with or without docetaxel (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric carcinoma3Adénocaecinome oeso-gastrique HER-2 négativeCritèresMétastatique1Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.frHEGP/Cochin
NCT03959293Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma2Adénocaecinome oeso-gastrique CritèresMétastatique2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03760822Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients2Adénocaecinome oeso-gastrique CritèresMétastatique2Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.frHEGP/Cochin
NCT03722108Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas 2Adénocaecinome oeso-gastrique CritèresMétastatique2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03693677First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI2Adénocaecinome du PancreasCritèresMétastatique1Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.frHEGP/Cochin
NCT04348045Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients (D19-02)2Adénocarcinome du PancreasBRCA / KRASSCritèresMétastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT04167007FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX3Adénocarcinome du PancreasCritèresMétastatique1Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.frHEGP/Cochin
NCT03656536A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma3Cholangiocarcinome Réarrangement FGFR2 CritèresLA-Métastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT03364530Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma2Intra-hepatic CholangiocarcinomeCritèresNon résecable-Non Métastatique2Julien Taieb : jtaieb75@gmail.comHEGP
NCT02502370Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma 3INTESTIN GRELECritèresAdjuvantAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT02260505 A randomized, multicentre, Phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tumours (GIST) 3GISTKIT positivityCritèresAdjuvantAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT03351296Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors 2tumeur neuroendocrine du pancréasCritèresLA-Métastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT02820857Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer2tumeur neuroendocrineCritèresLA-Métastatique2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03591731A GCO trial exploring the efficacy and safety of Nivolumab monotherapy or Nivolumab plus Ipilimumab in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) 2tumeur neuroendocrineCritèresLA-Métastatique2,3Julien Taieb : jtaieb75@gmail.com / romain.coriat@aphp.fr / francoise.lepimpec-barthes@aphp.frHEGP/Cochin
NCT03157128Phase 1/2 Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)1,2 : First in humanpan-tumoralRet-fusionCritèreslocally advanced or metastatic1,2jacques.medioni@aphp.frHEGP
NCT02715284Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET)1pan-tumoralCritères recurrent or advanced solid tumor2jacques.medioni@aphp.frHEGP
NCT03679767A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)2pan-tumoral (poumon & uro)PDL1 expressionCritèreslocally advanced or metastatic tumors1jacques.medioni@aphp.frHEGP
NCT02861573Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)1Adénocarcinome de la prostateCritèresmetastatic2jacques.medioni@aphp.fr / michael.peyromaure@aphp.frHEGP/Cochin
NCT03549715NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO)1,2Carcinome urothélial infiltrant de la vessieCritèresinvasiveAdjuvantjacques.medioni@aphp.fr / michael.peyromaure@aphp.frHEGP/Cochin
NCT03473743Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer1,2Carcinome urothélialCritèresmetastatic or locally advanced1,2jacques.medioni@aphp.frHEGP
NCT03390504A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations3Carcinome urothélialFGFRCritèresadvanced or metastatic2,3jacques.medioni@aphp.frHEGP
NCT03785925A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)2Carcinome urothélialCritèresmetastatic or locally advanced1jacques.medioni@aphp.frHEGP
NCT04197986Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations3Carcinome urothélialFGFR3Critèresinvasiveadjuvantjacques.medioni@aphp.frHEGP
NCT04209114A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer3Cancer de la vessieCritèresmuscle-invasivepré/post-opjacques.medioni@aphp.frHEGP
NCT03401788A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)2Carcinome rénal à cellules clairesgermline VHL alterationCritèreslocalized1jacques.medioni@aphp.frHEGP
NCT03976375Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)3Cancer du poumon non à petites cellules (NSCLC)Critèresmetastatic (Stage IV: M1a, M1b, M1c)2jacques.medioni@aphp.frHEGP
NCT04154956SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03)3Cancer du poumon non à petites cellules (NSCLC)CEACAM5 positiveCritèresmetastatic2jacques.medioni@aphp.frHEGP
NCT02960906A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer (BIONIKK)2Clear Cell Metastatic Renal Cell CarcinomaCritèresmetastatic  ([AJCC] Stage IV)1,2jacques.medioni@aphp.frHEGP
NCT03428217CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (CANTATA)2Renal cell carcinomaCritèresAdvanced,
Metastatic 
2,3jacques.medioni@aphp.frHEGP
NCT02231749Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)3Renal cell carcinomaCritèresAdvanced or
Metastatic 
1,2jacques.medioni@aphp.frHEGP
NCT03899155Pan Tumor Nivolumab Rollover Study2pan-tumoralCritèresjacques.medioni@aphp.frHEGP
NCT03809988PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA)2breast cancerER + or/and PgR + & HER2 –CritèresAdvanced1,2jacques.medioni@aphp.frHEGP
NCT03659136The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread2breast cancerER + or/and PgR + & HER2 –CritèresLocally advanced or metastatic1,2jacques.medioni@aphp.frHEGP
NCT03701334A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)3Breast cancerER + or/and PgR + & HER2 –Critèresearly invasive1jacques.medioni@aphp.frHEGP
NCT02760498Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma2Carcinome épidermoïde cutané avancéCritèreslocally advanced or metastatic1,2selim.aractingi@aphp.frCochin
NCT03469804Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma (KAPKEY)2Kaposi SarcomaCritèresProgressive disease>ou= 2selim.aractingi@aphp.frCochin
NCT03692065API-CAT STUDY for APIxaban Cancer Associated Thrombosis (API-CAT)3Cancer-associated Thrombosis – in gastro cancerCritèrestout stadetoute ligneromain.coriat@aphp.frCochin
NCT04282590A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)2Chemotherapy-induced Peripheral Neuropathy – in Gastro cancerCritères2romain.coriat@aphp.frCochin
NCT04526782ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)2Cancer du poumon non à petites cellules (NSCLC)BRAFCritèresStage IV2marie.wislez@aphp.frCochin
NCT02924376Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202)2CholangiocarcinomaFGFR2Critères >ou= 2romain.coriat@aphp.frCochin
NCT02997358Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma (LMS04)3Soft Tissue LeiomyosarcomaCritères metastatic or relapsed1romain.coriat@aphp.frCochin
NCT04083235A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)3Adenocarcinoma of the PancreasCritèresmetastatic1romain.coriat@aphp.frCochin
NCT04268121Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas (NEONEC)
2Neuroendocrine Carcinoma in gastro  Critères localizedneoadjuvantromain.coriat@aphp.frCochin
NCT04163900Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer3Biliary Tract CancerCritèreslocally advanced, unresectable or metastatic1 ou 2romain.coriat@aphp.frCochin
NCT02959879Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (PANACHE01)2Pancreatic Duct AdenocarcinomaCritèresResectable adenocarcinomaneoadjuvantromain.coriat@aphp.frCochin
NCT02676349Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)2Pancreatic CarcinomaCritères Borderline resectable statusneoadjuvantromain.coriat@aphp.frCochin
NCT04325425Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary (FOLFIRINEC)2Neuroendocrine Carcinoma in gastro  CritèresGrade 3 or high grade MiNEN1romain.coriat@aphp.frCochin
NCT03773302Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations3CholangiocarcinomaFGFR2 fusions/translocationsCritèresunresectable locally advanced or metastatic1romain.coriat@aphp.frCochin
NCT02313389Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma (BLOCAGE-01)3Primary Central Nervous System LymphomaCritèresnewly diagnosed1didier.bouscary@aphp.frCochin
NCT02416388Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1)2,3Acute Myeloid Leukemia (AML)Critèresnewly diagnosed de novo or secondary type AML1didier.bouscary@aphp.frCochin
NCT02619630Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old) (GRAALL-2014/T)2T-cell Adult Acute Lymphoblastic LeukemiaCritères 1didier.bouscary@aphp.frCochin
NCT03993912Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (IFM2017_03)3Multiple MyelomaCritères 1didier.bouscary@aphp.frCochin
NCT03799835Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN)3Bladder CancerCritèresT1 tumor and/or
High grade (WHO 2004) and/or
Grade 3 (WHO1973) and/or
Carcinoma in situ
1,2michael.peyromaure@aphp.fr / stephane.oudard@aphp.frCochin/HEGP
NCT03598270Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)3Ovarian CarcinomaCritèreshigh- grade serous or endometrioid ovarian, primary peritoneal or tubal carcinoma1,2,3bruno.borghese@aphp.fr / anne-sophie.bats@aphp.frCochin/HEGP
NCT04149574A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)3Bladder CancerCritèresPersistent or recurrent disease>ou= 2michael.peyromaure@aphp.frCochin
NCT04246489Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer2Uterine Cervical NeoplasmsCritèresadvanced unresectable and/or metastatic1,2bruno.borghese@aphp.frCochin
NCT04307277Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft Tissue Sarcoma (CHIC-STS01)3Soft tissue sarcomaCritèresResectable and localized diseasePéri-opfrancois.goldwasser@aphp.frCochin
NCT03822117Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-2072pan-tumoralFGFR genes mutations/translocationCritèresadvanced or metastatic or is surgically unresectable2francois.goldwasser@aphp.frCochin
NCT03249142Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV)1,2ovarian cancer,fallopian tubeCritèresnewly diagnosed1jerome.alexandre@aphp.frCochin
NCT02734004A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)1,2pan-tumoral (Sein, poumon, ovaire, cancer, gastro)CritèresAdvanced2francois.goldwasser@aphp.frCochin
NCT03517449Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician’s Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])3Endometrial NeoplasmsCritèresadvanced, recurrent or metastatic2jerome.alexandre@aphp.frCochin
NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent 3Endometrial NeoplasmsCritèresnewly diagnosed1jerome.alexandre@aphp.frCochin
NCT03486873Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study3pan-tumoralCritèresAdvanced or
Metastatic 
2francois.goldwasser@aphp.frCochin
NCT03924895Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer3Bladder cancerCritères Péri-opmichael.peyromaure@aphp.fr / stephane.oudard@aphp.frCochin/HEGP
NCT03784014Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC)3Soft Tissue SarcomaCritèresUnresectable locally advanced and/or metastatic STS1francois.goldwasser@aphp.frCochin
NCT03752216NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. (NiQoLe)4Ovarian CancerCritèreshigh grade epithelial ovarian cancer2jerome.alexandre@aphp.frCochin
NCT03643133Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (SARCOME13)2OsteosarcomaCritèreshigh-grade osteosarcomapost-opfrancois.goldwasser@aphp.frCochin
NCT03547973Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer2Urothelial CarcinomaCritères locally advanced or  localized muscle-invasive2michael.peyromaure@aphp.frCochin
NCT04209855A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)3Epithelial Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
Critères high-grade2bruno.borghese@aphp.frCochin
NCT02866370Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC)2Ovarian Clear Cell Carcinoma
Endometrial Clear Cell Carcinoma
CritèresProgressive or recurrent>ou= 2bruno.borghese@aphp.frCochin
NCT03630640Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP)2Hepatocellular CarcinomaCritères 2stanislas.pol@aphp.frCochin
NCT04463771Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.2Endometrial CancerCritèresAdvanced or Metastatic2jerome.alexandre@aphp.frCochin
NCT03745950UTOLA: UTerin OLAparib (UTOLA2Endometrial CancerMSI-High, MMR, POLE, FGFR mutations/alterationsCritèresadvanced/metastatic2jerome.alexandre@aphp.frCochin
NCT03833154Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4)3Carcinoma, Non-Small-Cell LungCritèresStage I to II NSCLCfrancoise.lepimpec-barthes@aphp.frHEGP
NCT03178552A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST2,3Non-Small Cell Lung CancerCritèresUnresectable stage IIIB or IV >1francoise.lepimpec-barthes@aphp.frHEGP
NCT03362177Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer3Chemotherapy-induced ThrombocytopeniaCritèresAllJulien Taieb : jtaieb75@gmail.comHEGP
NCT04478266Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer2,3Breast CancerER + and HER2 –Critèresloco-regional recurrent or metastatic1anne-sophie.bats@aphp.frHEGP
NCT03842982Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)3Ovarian CancerCritèresStage III2anne-sophie.bats@aphp.frHEGP
NCT04446117Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)3Metastatic Prostate Cancer
Prostate Adenocarcinoma
Critères 2stephane.oudard@aphp.frHEGP
NCT03138512A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914)3Renal Cell CarcinomaCritères >1stephane.oudard@aphp.frHEGP
NCT04109066Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)3Breast cancerER + and HER2 –CritèresLocalized invasive1anne-sophie.bats@aphp.frHEGP
NCT04100018A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX)3Prostate CancerCritèresmetastatic> ou = 2stephane.oudard@aphp.frHEGP
NCT03937219Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)3Renal Cell CarcinomaCritèresadvanced or metastatic (AJCC Stage IV)1stephane.oudard@aphp.frHEGP
NCT04003610 Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)3Urothelial CarcinomaFGFR3 mutation or rearrangementCritères metastatic or unresectable1 ou 2stephane.oudard@aphp.frHEGP
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors1,2pan-tumoralCritèresinoperable, locally advanced, metastatic, or recurrent1 ou 2jacques.medioni@aphp.frHEGP
NCT03556839Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc)3Carcinoma of the CervixCritèresmetastatic (stage IVB), persistent, or recurrent1anne-sophie.bats@aphp.frHEGP
NCT03815643Avelumab Program Rollover Study3pan-tumoralCritèresjacques.medioni@aphp.frHEGP
NCT03395197Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)3Metastatic Castration-Resistant Prostate Cancer (mCRPC)CritèresMetastatic2stephane.oudard@aphp.frHEGP
NCT03783442A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma3Esophageal Squamous Cell Carcinoma (ESCC)CritèresUnresectable, locally advanced recurrent or metastatic1Julien Taieb : jtaieb75@gmail.comHEGP
NCT03737643Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.3Advanced Ovarian CancerCritèresadvanced (Stage III-IV)1anne-sophie.bats@aphp.frHEGP
NCT03748641A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)3Castration-Resistant Prostatic CancerHRR gene alterationCritèresmetastatic1 ou 2stephane.oudard@aphp.frHEGP
NCT04791735Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma (LapCHC)Non Applicable / ChirurgieHepatocellular CarcinomaCritèresdavid.fuks@aphp.frCochin
NCT03469674PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer3Endometrial Cancer CritèresStage I, Stage IIcatherine.durdux@aphp.frHEGP
NCT04539938A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer2breast cancerHER2 +CritèresStade IV2jacques.medioni@aphp.frHEGP
NCT04622319A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)3breast cancerHER2 +CritèresStade III1jacques.medioni@aphp.frHEGP